Prostacyclin and steroidogenesis in goat ovarian cell types in vitro.
Granulosa, theca and corpus luteum cells of the goat ovary were isolated and incubated separately for 6 hours, with or without various modulators. Arachidonic acid (AA, 10 ng to 100 micrograms/ml), the precursor for prostaglandin synthesis, produced a dose-dependent increase in progesterone (P4) and estradiol-17 beta (E2) production by all the cell types. Prostaglandin synthetase inhibitors, aspirin (10(-6)-10(-3)M) and indomethacin (100 ng-1 mg/ml), produced a dose-dependent decrease in arachidonic acid-stimulated (100 micrograms/ml) steroid production. Prostacyclin synthetase stimulators, trapidil (1.6 micrograms- 1 mg/ml) and dipyridamole (10(-6)-10(-3)M), when added alone or along with AA, did not affect steroid production. Up to 100 micrograms/ml of U-51605 (9,11-azoprosta-5,13-dienoic acid), a prostacyclin synthetase inhibitor, did not inhibit basal or AA-stimulated steroid production. Prostacyclin (PGI2) and its stable analog 6 beta PGI1 (0.01-10 micrograms/ml) produced a dose-dependent increase in P4 and E2 production in all the three cell types. Increase at 1 and 10 micrograms/ml was significant in all cases. 6-keto-PGE1 (an active metabolite of PGI2 in certain systems) produced an increase in steroid production which was significant in theca at greater than or equal to 1 microgram/ml concentrations but had no significant effect on granulosa and corpus luteum cells at any dose level. 6-keto-PGF1 alpha (stable metabolite of PGI2) was without effect in the present system. The lack of effect of PGI2 at lower concentrations was not altered by either differentiation of the cells with FSH and testosterone or addition of steroid precursors, testosterone and pregnenolone. The present results indicate that AA-stimulated steroid production in the goat ovarian cell type is mediated by prostaglandins other than PGI2 though PGI2 itself can positively modulate the steroid production.
D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D004176:Dipyridamole / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology*; D004958:Estradiol / Q000096:biosynthesis; D005260:Female; D006041:Goats; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D010053:Ovary / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D011374:Progesterone / Q000096:biosynthesis; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011463:Prostaglandins H / Q000494:pharmacology; D013256:Steroids / Q000096:biosynthesis*; D014192:Trapidil / Q000494:pharmacology
D001095:Arachidonic Acids; D016861:Cyclooxygenase Inhibitors; D011463:Prostaglandins H; D013256:Steroids; D016718:Arachidonic Acid; D011374:Progesterone; D004958:Estradiol; C015014:azo analog I; D004176:Dipyridamole; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases; D014192:Trapidil; D001241:Aspirin; D007213:Indomethacin